Skip to main content
      On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
      Assessing Pain in Axial SpA
      SpA: ACR2025 Topic Panel
      Safety of CAR-T
      ACR2025 CAR-T Topic Panel
      In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.
      Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features. Non-invasive imaging is key in detecting large vessel involvement in GCA, as many of these patients do not experience signs or symptoms specific to this vascular disease (i.e.
      PsA Predictors
      ACR 2025 RA Topic Panel
      The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
      CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in
      ×